Eczema vaccinatum

Clinical Infectious Diseases

Volumn 54, Issue 6, 2012, Pages 832-840

  Reed, Jennifer L ^a   Scott, Dorothy E ^a   Bray, Mike ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TECOVIRIMAT; VACCINIA ANTIBODY;

ADAPTIVE IMMUNITY; ASTHMA; ATOPIC DERMATITIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; ECZEMA VACCINATUM; FOOD ALLERGY; HUMAN; INCIDENCE; INFECTION PREVENTION; INNATE IMMUNITY; KAPOSI VARICELLIFORM ERUPTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POXVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN DISEASE; VACCINATION REACTION;

ANIMALS; DERMATITIS, ATOPIC; ECZEMA; HUMANS; KAPOSI VARICELLIFORM ERUPTION; SKIN; SMALLPOX VACCINE;

EID: 84857510889     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir952     Document Type: Review

References (59)

1. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 2003; 58: 101-14. (Pubitemid 36556213)
2. Bray M, Wright ME. Progressive vaccinia. Clin Infect Dis 2003; 36: 766-74. (Pubitemid 36337981)
3. Centers for Disease Control and Prevention. Progressive vaccinia in a military smallpox vaccinee-United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 532-6.
4. Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008; 46: 1555-61. (Pubitemid 351706737)
5. Moses AE, Cohen-Poradosu R. Images in clinical medicine. Eczema vaccinatum-a timely reminder. N Engl J Med 2002; 346: 1287. (Pubitemid 34429460)
6. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281: 1201-8.
7. Beachkofsky TM, Carrizales SC, Bidinger JJ, Hrncir DE, Whittemore DE, Hivnor CM. Adverse events following smallpox vaccination with ACAM2000 in a military population. Arch Dermatol 2010; 146: 656-61.
8. Curth HO, Curth W, Garb J. Cutaneous complications of mass vaccination in New York City, 1947. J Invest Dermatol 1948; 10: 197.
9. Waddington E, Bray PT, Evans AD, Richards ID. Cutaneous complications of mass vaccination against smallpox in South Wales 1962. Trans St Johns Hosp Dermatol Soc 1964; 50: 22-42.
10. Copeman PW, Wallace HJ. Eczema vaccinatum. Br Med J 1964; 2: 906-8.
11. Greenberg M. Complications of vaccination against smallpox. Am J Dis Child 1948; 76: 492-502.
12. von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010; 28: 1209-16.
13. Kempe CH, Benenson AS. Smallpox and vaccinia. Pediatr Clin North Am 1955; 45: 19-32.
14. Blackford S, Roberts DL, Thomas PD. Cowpox infection causing a generalized eruption in a patient with atopic dermatitis. Br J Dermatol 1993; 129: 628-9. (Pubitemid 23336468)
15. Woodville. Report of a series of inoculations for the variolae vaccinae. London, United Kingdom: James Phillips and Son, 1799.
16. Martin HA. A most rare, possibly unique, case of general eruption of vaccinia. Med Rec 1882; 21: 393-6.
17. Kaposi M. Pathology and treatment of diseases of the skin. London: Balliere, Tindall and Cox, 1895.
18. Blochmann F. Ist die Schutzpockenimpfung mit allen notwendigen Kautelen umgeben? Tübingen: Franz Plietzecker, 1904.
19. Kempe CH. Smallpox vaccination of eczema patients with attenuated live vaccinia virus. Yale J Biol Med 1968; 41: 1-12.
20. Kempe CH. Passive immunity to vaccinia in newborns. I. Placental transmission of antibodies. Yale J Biol Med 1952; 24: 328-33.
21. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960; 26: 176-89.
22. Sharp JC, Fletcher WB. Experience of anti-vaccinia immunoglobulin in the United Kingdom. Lancet 1973; 1: 656-9.
23. Sussman MD, Grossman M. Complications of smallpox vaccination: effects of vaccinia immune globulin therapy. J Pediatrics 1965; 67: 1168-73.
24. Wise F, Sulzberger MB. Evolution of atopic dermatitis. Arch Derm Syphilol 1935; 32: 451-63.
25. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol 2004; 114: 150-8. (Pubitemid 39005132)
26. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980; 92: 44-7.
27. Suarez-Farinas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011; 127: 954-64. e1-4.
28. Holm EA, Wulf HC, Thomassen L, Jemec GB. Assessment of atopic eczema: clinical scoring and noninvasive measurements. Br J Dermatol 2007; 157: 674-80. (Pubitemid 47389891)
29. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233-46.
30. Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009; 124: 1235-44. e58.
31. Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999; 18: 4657-68. (Pubitemid 29415520)
32. Higuchi K, Hara J, Okamoto R, Kawashima M, Imokawa G. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 2000; 350: 747-56.
33. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357: 1608-19. (Pubitemid 47598403)
34. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-94.
35. Li C, Lasse S, Lee P, et al. Development of atopic dermatitis-like skin disease from the chronic loss of epidermal caspase-8. Proc Natl Acad Sci USA 2010; 107: 22249-54.
36. Descargues P, Deraison C, Prost C, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsinlike hyperactivity in Netherton syndrome. J Invest Dermatol 2006; 126: 1622-32.
37. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011; 127: 1420-32.
38. Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41: 298-310.
39. Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004; 113: 756-63. (Pubitemid 38530433)
40. Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol 2011; 131: 329-37.
41. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-60.
42. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing ''T22'' T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009; 123: 1244-52. e2.
43. Chen L, Martinez O, Venkataramani P, Lin SX, Prabhakar BS, Chan LS. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol 2005; 139: 189-201. (Pubitemid 40222836)
44. Kawakami Y, Tomimori Y, Yumoto K, et al. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med 2009; 206: 1219-25.
45. Oyoshi MK, Elkhal A, Kumar L, et al. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc Natl Acad Sci USA 2009; 106: 14954-9.
46. Scott JE, ElKhal A, Freyschmidt EJ, et al. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol 2007; 120: 1382-8. (Pubitemid 350216593)
47. Freyschmidt EJ, Mathias CB, Diaz N, et al. Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. J Immunol 2010; 185: 1295-302.
48. Freyschmidt EJ, Mathias CB, MacArthur DH, et al. Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus. J Allergy Clin Immunol 2007; 119: 671-9.
49. Ellis FA. Eczema vaccinatum: its relationship to generalized vaccinia. JAMA 1935; 104: 1891-4.
50. McKhann CF, Ross RA. Generalized vaccinia and eczema vaccinatum. Med Clin North America 1938; 22: 785-94.
51. Gerstein W, Shelley WB. Eczema vaccinatum as a complication of keratosis follicularis. N Engl J Med 1960; 262: 1166-8.
52. Buller RM, Chakrabarti S, Moss B, Fredrickson T. Cell proliferative response to vaccinia virus is mediated by VGF. Virology 1988; 164: 182-92.
53. Anderson T. Kaposi's varicelliform dermatosis: a virus pyodermia. Br J Dermatol Syph 1949; 61: 157-66.
54. Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol 2009; 124: 260-9. 9 e1-7.
55. Fries JH, Borne S, Barnes HL. Varicelliform eruption of Kaposi due to vaccinia virus complicating atopic eczema. J Pediatrics 1948; X: 532-42.
56. Cohen JI, Hohman P, Preuss JC, Li L, Fischer SH, Fedorko DP. Detection of vaccinia virus DNA, but not infectious virus, in the blood of smallpox vaccine recipients. Vaccine 2007; 25: 4571-4. (Pubitemid 46734536)
57. Donnally HH, Nicholson MM. A study of vaccination in five hundred new-born infants. JAMA 1934; 103: 1269-74.
58. Reynolds AH, Joos HA. Eczema vaccinatum. Pediatrics 1958; 22: 259-67.
59. Fisher RW, Reed JL, Snoy PJ, et al. Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin. Clin Vaccine Immunol 2011; 18: 67-74.